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Background: Neurofibromatosis type 1 (NF1) is one of the most common genetic diseases in humans and has
widely variable expressivity. Oral manifestations are common, but there are no studies that investigated functional
alterations in salivary glands in NF1. Our aim was to evaluate the salivary flow rate in NF1 individuals, comparing to
a control group, and to investigate the possible causes and some consequences of salivary gland alteration.
Methods: This is a case–control study that evaluated the salivary flow rate of NF1 individuals (n = 49) and
compared to an age and sex-matched control group. We have also investigated the possible causes and
consequences of hyposalivation in NF1 individuals through anamnesis, a specific questionnaire, physical
examination, tongue coating evaluation and cytopathological exam to assess the prevalence of oral
candidiasis.
Results: Hyposalivation at rest was present in 59% (29/49) of NF1 individuals in contrast to 22% (11/49) in
the control group, being statistically significant (P <0.0001; Wilcoxon rank-sum test). The analysis of the adjusted residual
showed that the prevalence of hyposalivation in NF1 individuals (46.9%) was 4-fold higher than in controls (10.2%).
None of the possible causes of hyposalivation (medications, low liquid intake, caffeinated or stimulant drink use, mouth
breathers, alcohol, smoke and plexiform neurofibroma close to or involving major salivary glands areas) had important
impact on the salivary flow rate in NF1 individuals.
Conclusions: Hyposalivation may be a consequence of NF1, as occurs in other genetic diseases. More studies are
necessary to understand if there is and what is the relationship between NF1 and hyposalivation.
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Neurofibromatosis 1 (NF1, OMIM 162200) is one of the
most common genetic diseases and has widely variable
expressivity [1]. Oral manifestations are common, [2-6]
but there are no studies that investigated functional
alterations in salivary glands in NF1. Our aim was to
evaluate the salivary flow rate in NF1 individuals, com-
paring to a control group, and to investigate the possible
causes and some consequences of salivary gland alteration.* Correspondence: karingcunha@gmail.com
1Postgraduate Program in Pathology, School of Medicine, Universidade
Federal Fluminense, Niterói, RJ, Brazil
2Neurofibromatosis National Center (Centro Nacional de Neurofibromatose),
Rio de Janeiro, RJ, Brazil
Full list of author information is available at the end of the article
© 2015 Cunha et al.; licensee BioMed Central.
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.Methods
This case–control study was approved by the Ethics
Committee (#31640/2012) and conducted at Oral Diag-
nosis Ambulatory and Pathological Anatomy Service of
Antônio Pedro University Hospital of Universidade Federal
Fluminense, Brazil.
The study group was composed of 49 NF1 individuals,
according to clinical criteria [7]. To compare the sialo-
metry values of NF1 individuals, a sex and age-matched
control group (n=49) composed by non-NF1 individuals
was included. Data about smoking, alcohol use, and in-
take of hyposalivation-inducing drugs was obtained from
both groups.
Sialometry (unstimulated whole saliva flow rate) was
performed between 8:00–11:30 AM and the participantsThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,





Age (years) 42.5 ± 14.8† 42.5 ± 14.8† –
Sex (female/male) 35/14 (2.5:1.0) 35/14 (2.5:1.0) –
Smoker 4 (8%) 9 (18%) 0.227
Alcohol user 8 (16%) 10 (20%) 0.774
Hyposalivation-inducing drugs 14 (28%) 18 (36%) 0.344
NF1, Neurofibromatosis 1.
*P value is from McNemar χ2 test; † Results indicate
mean ± standard deviation.
Table 3 Hyposalivation and oral dryness questionnaire in
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After discarding all the saliva present in the mouth,
saliva was collected for 5 minutes without stimulus. The
salivary flow rate (mL/min) was calculated and classified:
normal: ≥0.3; low: ≥0.1 and <0.3; very low: <0.1.
Tongue coating was evaluated according to previous
studies [8,9], using digital photographs. The tongue dor-
sum area was divided into nine equal sections and each
section was assigned a value: 0 = no; 1 = thin, 2 = thick
coating. The sum of the results of each section was cal-
culated, divided by 18 and multiplied by 100 to achieve
the tongue coating index (TCI) percentage score.
Oral candidiasis was investigated by clinical and cyto-
pathology exam through scrapping the tongue dorsum
with a cytobrush. Glass slides stained with Papanicolaou
and Periodic Acid-Schiff were analyzed according to
specific criteria [10].
NF1 participants also answered to a questionnaire
(Table 1).
Results
Additional files 1, 2 and 3 show details of the results.
Table 2 summarizes the sample characteristics. There
was no heterogeneity between the study and control
group according to smoking, alcohol use and intake of
medications that could cause hyposalivation. Four (8%)
NF1 participants had plexiform neurofibromas close to
or involving the major salivary glands areas and only one
(25%) had hyposalivation.
In NF1 individuals, 59% (29/49) had hyposalivation;
32% (16/49) had severe hyposalivation. In the control
group, 22% (11/49) of individuals had hyposalivation; 8%
(4/49) presented severe hyposalivation. There was a
statistically significant difference between the sialometry
values of the study and control group (P < 0.0001; Wilcoxon
rank-sum test). There was a statistically significantTable 1 Questionnaire used in the study group (with NF1)
Questions Response
Oral Dryness Questionnaire Yes No
1. Do you fell dry oral mucosa sensation? Yes No
2. Do you feel dry lips sensation? Yes No
3. Do you have difficult to swallow dry food? Yes No
4. Do you drink liquids to aid swallowing dry food? Yes No
5. Do you feel change in saliva viscosity? Yes No
6. Do you feel a decreased amount of saliva in your mouth? Yes No
7. Do you feel enough or increased amount of saliva in your
mouth?
Yes No
Other Questions Yes No
8. Do you intake at least 2 liters of liquid daily? Yes No
9. Do you commonly drink caffeinated or stimulant drinks? Yes No
10. You are a mouth breather? Yes Noassociation between NF1 individuals and presence of
hyposalivation (P = 0.001; McNemar’s χ2 test). The ana-
lysis of the adjusted residual showed that the prevalence
of hyposalivation in NF1 individuals (46.9%) was 4-fold
higher than in controls (10.2%).
Forty-six NF1 participants answered to the question-
naire. The number of positive answers per individual to
the oral dryness questions was assessed to investigate
them as possible predictor of hyposalivation. The results
are shown in Tables 3–4.
Oral candidiasis was present in 22% (11/49) of NF1
individuals. Of these, 54% (6/49) had no clinical signs or
symptoms of candidiasis, 36% (3/49) had erythematous
and 9% (1/49) pseudomembranous candidiasis.
Fifty-five percent (27/49) of NF1 individuals had more
than 50% and 16% had more than 80% of the tongue
covered by coating. The mean of TCI was 50% (standard(%) (IC 95%)
1. Do you fell dry oral
mucosa sensation?
9 (18) 1.8 (0.4 – 7.3) 0.51
2. Do you feel dry lips
sensation?
10 (20) 0.8 (0.2 – 2.6) 0.76
3. Do you have difficult to
swallow dry food?
6 (12) 1.5 (0.3 – 7) 0.71
4. Do you drink liquids to
aid swallowing dry food?
14 (28) 1.8 (0.5 – 6.1) 0.37
5. Do you feel change in
saliva viscosity?
11 (22) 1.9 (0.5 – 6.9) 0.36
6. Do you feel a decreased
amount of saliva in your
mouth?
8 (16) 0.9 (0.2 – 3.2) 0.88
7. Do you feel enough or
increased amount of saliva
in your mouth?
3 (6) 0.4 (0.09 – 2) 0.42
UWSFR, unstimulated whole saliva flow rate; OR (IC 95%), Odds ratio and 95%
of confidence interval.
*P value is from Qui-Square analysis or Fisher’s exact test.
Table 4 Score of positive answers from oral dryness
assessment questionnaire according to hyposalivation in




Hyposalivation (%) OR (IC 95%) P**
None 7 (14) 0.9 (0.2 – 3.7) 0.97
One 8 (16.3) 0.6 (0.1 – 3) 0.7
Two 4 (8.1) 0.4 (0.1 – 2.1) 0.45
Three 7 (14) 2.9 (0.5 – 16.2) 0.27
Four 2 (4) 1.7 (1.3 – 2.2) 0.5
Five 2 (4) 1.4 (0.1 – 17.1) 1.0
Six 2 (4) 0.6 (0.8 – 5.3) 1.0
UWSFR, Unstimulated whole saliva flow rate; OR (IC 95%), Odds ratio and 95%
of confidence interval.
*Considering the first six questions of the Oral Dryness Questionnaire, **P
value is from Qui-Square analysis or Fisher’s exact test.
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quartile = 72).
Any of the investigated variables were associated with
hyposalivation in NF1 individuals (Table 5).
Discussion
We showed that NF1 individuals present high preva-
lence (59%) of hyposalivation comparing to a control
group (P < 0.001), with a proportion 4-fold higher than
the controls.
Xerostomia often occurs when sialometry value is re-
duced by about 50% [11]. Due to this lack of correlation
between xerostomia and hyposalivation, some authors
have investigated whether positive answers to other








Intake less than 2 liters of liquid daily




UWSFR, Unstimulated whole saliva flow rate; OR (95% IC), Odds ratio and 95% of co
*P value is from Qui-square analysis and Fisher’s exact tests for categorical variables and M
indicate mean± standard deviation.correlation with sialometry values [11]. In our study,
hyposalivation was not associated with xerostomia in
NF1 individuals, neither with other questions from the
oral dryness questionnaire.
Xerostomia can also occur in individuals with normal
sialometry values [11,12]. It can occur in mouth breathers
or because of changes in the sialochemistry, viscoelastic
properties of saliva or by sensory alterations. In the
present study, there was no NF1 individual who com-
plained of xerostomia and did not present hyposalivation.
Saliva exerts many functions in oral cavity, including
the control of the composition of the microflora. We
found 22% of NF1 participants with cytological evidence
of oral candidiasis and 55% with 50% of the tongue covered
by coating, but none were associated with hyposalivation.
None of the investigated causes of hyposalivation (medi-
cations, low liquid intake, caffeinated or stimulant drink
use, alcohol, and smoke) were associated with low salivary
flow rate in NF1. Moreover, only 4 (8%) NF1 individuals
had plexiform neurofibromas in areas of major salivary
glands, which could cause atrophy of the acinar cells by
compression or infiltration by the tumor cells, and just
one of them had hyposalivation.
Alterations in the salivary glands (acini and ducts)
caused by mutations in the NF1 gene may be a possible
explanation for the high prevalence of hyposalivation in
NF1 individuals. Neurofibromin is a negative regulator of
the Ras pathways and there is a complex signaling cross-
talks between neurofibromin and other members of the
superfamily of small GTPases, including Rho binding do-
main [13]. Rho family of small GTPases presents a crucial
role in lumen morphogenesis of salivary glands in animal
models and in acinus formation in human salivary glandd consequences in study group (with NF1)
Hyposalivation
UWSFR OR (95% IC) P*
43 ± 15.6† – 0.77
23/6 (3.8/1) 2.5 (0.7-9.0) 0.14
1 (3.4%) 0.2 (0.01-2.1) 0.29
1 (3.4%) 0.2 (0.01-2.1) 0.29
5 (17%) 1.1 (0.2-5.6) 1.0
15 (51%) 1.6 (0.5-5.0) 0.41
8 (27%) 1.7 (0.5-5.6) 0.36
13 (44%) 1.2 (0.3-4.1) 0.68
14 (48%) 1.4 (0.4-4.8) 0.51
7 (24%) 1.2 (0.3-5.0) 1.0
44.4 ± 27.3† – 0.05
nfidence interval.
ann–Whitney test for numerical variables; †Results of age and tongue coating index
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bromin is strongly expressed in ductal cells of the parotids.
Other salivary glands were not evaluated in that study.
Moreover, the volume and type of saliva is controlled
by autonomic nervous system and the blood supply to
the glands influences the salivary secretion. Since neuro-
fibromin is expressed in peripheral and central nervous
system, as well as in blood vessel smooth muscle and
endothelial cells [18-20], alteration in autonomic ner-
vous system and in blood flux to the salivary glands may
also be involved in hyposalivation in NF1 individuals.
Conclusions
Hyposalivation may be a consequence of NF1, as occurs
in other genetic diseases. More studies are necessary to
understand if there is and what is the relationship
between NF1 and hyposalivation.
Availability of supporting data
The data sets supporting the results of this article are in-
cluded within the paper and its additional files.
Additional files
Additional file 1: Details of the clinical data of the study group
(NF1 group).
Additional file 2: Details of the clinical data of the control group.
Additional file 3: Details of the results of the oral dryness
assessment questionnaire (NF1 group).
Abbreviations
NF1: Neurofibromatosis 1; TCI: Tongue coating index; UWSFR: Unstimulated
whole saliva flow rate; OR: Odds ratio; IC: Confidence interval.
Competing interests
The authors declared that they have no competing interests.
Authors’ contributions
KSC designed the project, supervised and coordinated the whole process
and wrote the manuscript. RRLAP and LVA attended the NF1 participants
and collected the data from this group. RRLAP and EBL performed the
tongue coating index analysis. EBL, PNA and LMAS obtained the data from
the control group. RERM, PNA and EBL participated in writing the
manuscript. RERM were involved in statistical analysis and data interpretation.
EPD was responsible for cytopathology analysis and critically reviewed the
manuscript. All authors read and approved the final manuscript.
Acknowledgment
The authors thank the Postgraduate Program in Pathology of Universidade
Federal Fluminense for its most valuable Oral Diagnosis Ambulatory, which
made possible the attendance of NF1 participants. The present research
received no specific grant from any funding agency in the public,
commercial, or not-for-profit sectors.
Author details
1Postgraduate Program in Pathology, School of Medicine, Universidade
Federal Fluminense, Niterói, RJ, Brazil. 2Neurofibromatosis National Center
(Centro Nacional de Neurofibromatose), Rio de Janeiro, RJ, Brazil. 3School of
Dentistry, Universidade Federal Fluminense, Niterói, RJ, Brazil. 4Department of
Pathology, School of Medicine, Universidade Federal Fluminense, Niterói, RJ,
Brazil.Received: 4 January 2015 Accepted: 10 February 2015
References
1. Cunha KSG, Geller M. Advances in Neurofibromatosis Research. New York:
Nova Science Publishers Inc; 2011.
2. Shapiro SD, Abramovitch K, Van Dis ML, Skoczylas LJ, Langlais RP, Jorgenson
RJ, et al. Neurofibromatosis: oral and radiographic manifestations. Oral Surg
Oral Med Oral Pathol. 1984;58:493–8.
3. Cunha KS, Barboza EP, Dias EP, Oliveira FM. Neurofibromatosis type I with
periodontal manifestation. A case report and literature review. Br Dent J.
2004;196:457–60.
4. D’Ambrosio JA, Langlais RP, Young RS. Jaw and skull changes in
neurofibromatosis. Oral Surg Oral Med Oral Pathol. 1988;66:391–6.
5. Bardellini E, Amadori F, Flocchini P, Conti G, Piana G, Majorana A. Oral
findings in 50 children with neurofibromatosis type 1. A case control study.
Eur J Paediatr Dent Off J Eur Acad Paediatr Dent. 2011;12:256–60.
6. Javed F, Ramalingam S, Ahmed HB, Gupta B, Sundar C, Qadri T, et al. Oral
manifestations in patients with neurofibromatosis type-1: a comprehensive
literature review. Crit Rev Oncol Hematol. 2014;91:123–9.
7. Stumpf DA, Alksne JF, Annegers JF, Brown SS, Conneally PM, Housman D,
et al. Conference statement. National Institutes of Health Consensus
Development Conference. Arch Neurol. 1988;45:575–8.
8. Mantilla Gómez S, Danser MM, Sipos PM, Rowshani B, van der Velden U, van
der Weijden GA. Tongue coating and salivary bacterial counts in healthy/
gingivitis subjects and periodontitis patients. J Clin Periodontol.
2001;28:970–8.
9. Shimizu T, Ueda T, Sakurai K. New method for evaluation of tongue-coating
status. J Oral Rehabil. 2007;34:442–7.
10. Picciani BLS, Silva-Junior GO, Michalski-Santos B, Avelleira JCR, Azulay DR,
Pires FR, et al. Prevalence of oral manifestations in 203 patients with psoriasis.
J Eur Acad Dermatol Venereol JEADV. 2011;25:1481–3.
11. Löfgren CD, Wickström C, Sonesson M, Lagunas PT, Christersson C. A
systematic review of methods to diagnose oral dryness and salivary gland
function. BMC Oral Health. 2012;12:29.
12. Van der Putten G-J, Brand HS, Schols JMGA, de Baat C. The diagnostic suitability
of a xerostomia questionnaire and the association between xerostomia,
hyposalivation and medication use in a group of nursing home residents. Clin
Oral Investig. 2011;15:185–92.
13. Crema VO, Hamassaki DE, Santos MF. Small Rho GTPases are important for
acinus formation in a human salivary gland cell line. Cell Tissue Res.
2006;325:493–500.
14. Xu N, Keung B, Myat MM. Rho GTPase controls invagination and cohesive
migration of the Drosophila salivary gland through Crumbs and Rho-kinase.
Dev Biol. 2008;321:88–100.
15. Vallée B, Doudeau M, Godin F, Gombault A, Tchalikian A, de Tauzia M-L,
et al. Nf1 RasGAP inhibition of LIMK2 mediates a new cross-talk between
Ras and Rho pathways. PLoS One. 2012;7:e47283.
16. Ozawa T, Araki N, Yunoue S, Tokuo H, Feng L, Patrakitkomjorn S, et al. The
neurofibromatosis type 1 gene product neurofibromin enhances cell
motility by regulating actin filament dynamics via the Rho-ROCK-LIMK2-cofilin
pathway. J Biol Chem. 2005;280:39524–33.
17. Kimura N, Watanabe T, Fukase M, Wakita A, Noshiro T, Kimura I.
Neurofibromin and NF1 gene analysis in composite pheochromocytoma
and tumors associated with von Recklinghausen’s disease. Mod Pathol Off
J U S Can Acad Pathol Inc. 2002;15:183–8.
18. Foster PN, Stewart M, Lowe JS, Atkinson M. Achalasia like disorder of the
oesophagus in von Recklinghausen’s neurofibromatosis. Gut.
1987;28:1522–6.
19. Okazaki K, Kakita A, Tanaka H, Kimura K, Minagawa M, Morita T, et al.
Widespread ischemic brain lesions caused by vasculopathy associated with
neurofibromatosis type 1. Neuropathol Off J Jpn Soc Neuropathol.
2010;30:627–33.
20. Danglot G, Régnier V, Fauvet D, Vassal G, Kujas M, Bernheim A.
Neurofibromatosis 1 (NF1) mRNAs expressed in the central nervous system
are differentially spliced in the 5′ part of the gene. Hum Mol Genet.
1995;4:915–20.
